Topic: pay for delay deals
In an effort to keep drug prices down, California is looking to end a longtime pharma practice that keeps generic challengers off the market.
Mired in pay-for-delay suits over narcolepsy drug Provigil, Teva’s Cephalon is looking to clear the field. A $65.8 million settlement could help.
Many years into an investigation over a "pay-for-delay" payment on Opana ER, the FTC says Impax violated competition law.
A pay-for-delay case against GlaxoSmithKline that has been kicking around for years has finally been decided, and GSK lost.
Sun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a of a host of issues that contributed to a 74% profit slide.
Merck & Co. and Upsher-Smith agreed to settle with drug purchasers that alleged the companies inked a deal to delay generic competition to Merck's K-Dur.
Teva is eager to start moving in the right direction after a particularly rocky 2016. Problem is, it’s still paying for pay-for-delay decisions made by its products’ previous owners.
Teva has agreed to settlement terms to resolve a lengthy class action lawsuit in California.
The EU’s pushback on pay-for-delay arrangements among drugmakers is being tested today as its top court considers appeals from half a dozen drugmakers fined heavily over deals with Denmark’s Lundbeck that authorities said were so cozy as to make them anticompetitive.
GlaxoSmithKline’s U.K. offices have taken exception to a major multimillion-pound fine levied by the country’s market watchdog, saying its conduct was “objectively justified.”